The Food and Drug Administration Friday issued warning letters to all three duodenoscope manufacturers for failing to comply with a 2015 order to conduct postmarket surveillance studies to determine whether health care facilities are able to properly clean and disinfect the devices. “The FDA has taken important steps to improve the reprocessing of duodenoscopes, and we’ve seen a reduction in reports of patient infections, but we need the required postmarket studies to determine whether these measures are being properly implemented in real-world clinical settings and whether we need to take additional action to further improve the safety of these devices,” said Jeff Shuren, M.D., director of the FDA’s Center for Devices and Radiological Health. “We expect these device manufacturers to meet their study obligations to ensure patient safety.” The letters were sent to Olympus, Fujifilm and Pentax, who are expected to submit a plan by March 24 outlining how study milestones will be achieved.

Related News Articles

Headline
Boston Medical Center, a private, not-for-profit, equity-led academic medical center, is the winner of AHA’s 2024 Foster G. McGaw Prize for its leadership and…
Headline
WellSpan Health in York, Pa., will receive the 2024 AHA Quest for Quality Prize for its commitment to improving quality through its health equity strategic…
Perspective
Patient safety is the top priority of every caregiver. Hospitals and health systems never stop searching for ways to improve quality, performance and results…
Blog
The greatest success story of the 20th century is longevity. This is especially true in the United States, where average life expectancy at birth rose by more…
Headline
The AHA the week of July 8 released its Quality Collective Report, which explores quality, safety and performance improvement strategies and insights from…
Headline
In a new “Safety Speaks” conversation, Harry S. Smith, board chair of Valley Health System and member of the AHA Committee on Governance, discusses how Valley…